Although there is no sufficient evidence supporting that mutated PIK3CA genes or mutated PI3K-AKT pathways are associated with treatment benefit of anthracyclines for BC, the interaction between mutated PIK3CA gene/PI3K-AKT pathway and chemotherapy agents, like anthracyclines and taxanes, has been indicated in vitro (41). This evidence concerns the gene AKT1 and breast cancer.